The National Research Center for Epidemiology and Microbiology named after N. F. Gamaleya, founded in 1891, is a leading research institution in the field of epidemiology and microbiology. It is known for its work in vaccine development and infectious disease research. The center collaborates with various institutions and has developed several vaccines, including those for COVID-19, Ebola, and other infectious diseases.
We're tracking Национальный Исследовательский Центр Эпидемиологии И Микробиологии Имени Н. Ф. Гамалеи's market expansion
How Национальный Исследовательский Центр Эпидемиологии И Микробиологии Имени Н. Ф. Гамалеи's international expansion compares to its competitors
Национальный Исследовательский Центр Эпидемиологии И Микробиологии Имени Н. Ф. ГамалеиYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Национальный Исследовательский Центр Эпидемиологии И Микробиологии Имени Н. Ф. ГамалеиYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Russia's Sputnik V vaccine became the most exported drug in Russian history, with total exports worth $1.3 billion, according to RDIF CEO Kirill Dmitriev.
Russia's Gamaleya Center has developed a vaccine against Omicron BA.4 and BA.5 variants, ready for trials. Based on Sputnik V, it awaits government approval for registration.
Gamaleya Center created a vaccine protecting against multiple flu strains for 3-4 years, including swine flu and possibly bird flu.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Национальный Исследовательский Центр Эпидемиологии И Микробиологии Имени Н. Ф. Гамалеи's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
